Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research Institute, is the principal investigator and international coordinator of a controlled phase 2 drug study that, for the first time in 20 years, is achieving positive results for cognitive complications in Parkinson’s disease. Sant Pau Hospital has also participated as a patient recruitment centre for the study.

Annex

Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream